Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring: developments and future prospects (Q40109451)

17 September 2017

Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring: developments and future prospects (English)

1 reference

bladder urothelial carcinoma

17 September 2017

1 reference

1

Shahrokh F Shariat

1 reference

17 September 2017

Jose A Karam

2

1 reference

PubMed ID

20477438

17 September 2017

Jay D Raman

series ordinal

3

1 reference

17 September 2017

1 April 2008

1 reference

17 September 2017

Biomarkers in Medicine

1 reference

17 September 2017

2

1 reference

17 September 2017

2

1 reference

17 September 2017

165-180

1 reference

17 September 2017

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Biology and management of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Prognostic markers in bladder cancer: a contemporary review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Can biological markers replace cystoscopy? An update

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Correlation of office-based cystoscopy and cytology with histologic diagnosis: how good is the reference standard?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part I: definition, detection, prevalence, and etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Dipstick urinalysis screening of asymptomatic adults for urinary tract disorders. I. Hematuria and proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

The application of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Identification of a nuclear protein matrix.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

NuMA is required for the proper completion of mitosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Analysis of genetic alterations in normal bladder urothelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Evaluation of urinary bladder cancer antigen as a marker for diagnosis of transitional cell carcinoma of the urinary bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

The early detection and diagnosis of bladder cancer: a critical review of the options.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Urine based markers of urological malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Further study of fibrinogen degradation products in bladder cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Functional characterization of the bladder cancer marker, BLCA-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

HA-HAase urine test. A sensitive and specific method for detecting bladder cancer and evaluating its grade

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Fas and other cell death signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Prognostic significance of soluble Fas in the serum of patients with bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Transitional cell carcinoma expresses high levels of Fas ligand in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Survivin, versatile modulation of cell division and apoptosis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Telomere length regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Telomeres and their synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Structure and function of telomeres

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Specific association of human telomerase activity with immortal cells and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Prostate-specific antigen (PSA), PSA density and age-adjusted PSA reference values in screening for prostate cancer--a study of a randomly selected population of 2,400 men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Value of PSA (prostate-specific antigen) in the detection of prostate cancer in patients with urological symptoms. Results of a multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: a utility analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

Highly specific urine-based marker of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17520363.2.2.165

21 January 2018

Identifiers

DOI

10.2217/17520363.2.2.165

1 reference

17 September 2017

1 reference

PubMed ID

20477438